Obstetrics and gynecology
-
Obstetrics and gynecology · Nov 2018
Randomized Controlled Trial Multicenter StudyElagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. ⋯ ClinicalTrials.gov, NCT01817530; EU Clinical Trial Register, 2013-000082-37.